Mental Health Bulletin, July 2008 s5

GI Cancers November 2015

This bulletin covers aspects of esophageal, gastric, intestinal and colorectal cancers and should be of interest to multidisciplinary teams working in this area.

Sections can include:  Combined Modality Therapies  Drug and Targeted Therapies  Pathology, Staging, Polymorphisms & Biomarkers  Prognosis, Survival & Risk Factors  Radiotherapy & Imaging  Supportive Care & Symptom Management  Surgery

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by: Kirsty Coltart Subject Librarian Beatson West of Scotland Cancer Centre 0141 301 7285, [email protected] General

Davidson M, Okines AF and Starling N. (2015). Current and Future Therapies for Advanced Gastric Cancer. Clinical Colorectal Cancer 14,4:239-250.

ESMO Clinical Practice Guidelines: Cancer of the pancreas. September 2015

Lee M, Gibbs P and Wong R. (2015). Multidisciplinary Management of Locally Advanced Rectal Cancer-An Evolving Landscape? Clinical Colorectal Cancer 14,4:251-261.

Mahipal A, Choi M and Kim R. (2015). Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand? Journal of the National Comprehensive Cancer Network 13,10:1281-1292.

Millan M, Merino S, Caro A, et al. (2015). Treatment of colorectal cancer in the elderly. World Journal of Gastrointestinal Oncology 7,10:204-220.

Parakh S, Wong HL, Rai R, et al. (2015). Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. Journal of Geriatric Oncology 6,5:387-394..

Combined Modality Therapies

Allegra CJ, Yothers G, O'Connell MJ, et al. (2015). Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Journal of the National Cancer Institute 107,11:

Bokemeyer C, Stein A, Ridwelski K, et al. (2015). A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 18,4:833-842.

Cancer Care Ontario: Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection. September 2015

Chawla S, Katz AW, Rauh SM, et al. (2015). Can Surgery be Avoided After Preoperative Chemoradiation for Rectal Cancer in the Era of Organ Preservation? Current Review of Literature. American Journal of Clinical Oncology 38,5:534-540.

Garcia-Aguilar J, Renfro LA, Chow OS, et al. (2015). Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncology 16,15:1537-1546.

Hategan M, Cook N, Prewett S, et al. (2015). Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. Diseases of the Esophagus 28,7:612-618.

Jung M, Shin SJ, Koom WS, et al. (2015). A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. International journal of radiation oncology, biology, physics 93,5:1015-1022.

Newton AD, Datta J, Loaiza-Bonilla A, et al. (2015). Neoadjuvant therapy for gastric cancer: current evidence and future directions. Journal of Gastrointestinal Oncology 6,5:534-543.

Park SH, Sohn TS, Lee J, et al. (2015). Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology 33,28:3130-3136.

GI Cancers, November 2015 2 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Resende HM, Jacob LF, Quinellato LV, et al. (2015). Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database of Systematic Reviews 10,008531.

Ryan JE, Warrier SK, Lynch AC, et al. (2015). Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Disease 17,10:849-861.

Shapiro J, van Lanschot JJ, Hulshof MC, et al. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology 16,9:1090-1098.

Stiles BM, Salzler GG, Nasar A, et al. (2015). Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomy. European Journal of Cardio-Thoracic Surgery 48,3:455-460.

Trip AK, Stiekema J, Visser O, et al. (2015). Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study. Acta Oncologica 54,10:1754-1762.

Drug & Targeted Therapies

Becerra AZ, Probst CP, Tejani MA, et al. (2015). Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused. Surgery 158,3:692-699.

Braam HJ, Schellens JH, Boot H, et al. (2015). Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Critical Reviews in Oncology-Hematology 95,3:282-296.

Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al. (2015). Maintenance strategies after first- line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncology 16,13:1355-1369.

Jakobsen A, Andersen F, Fischer A, et al. (2015). Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncologica 54,10:1747-1753.

Kay A, Yun L, Taback N, et al. (2015). Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice. Cancer 121,16:2791-2798.

Landre T, Uzzan B, Nicolas P, et al. (2015). Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. International journal of colorectal disease 30,10:1305-1310.

Lim B and Jiang Y. (2015). Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease". Current Clinical Pharmacology 10,4:267-278.

Lim SH, Kim TW, Hong YS, et al. (2015). A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. British journal of cancer 113,10:1421-1426.

Malietzis G, Mughal A, Currie AC, et al. (2015). Factors Implicated for Delay of Adjuvant Chemotherapy in Colorectal Cancer: A Meta-analysis of Observational Studies. Annals of Surgical Oncology 22,12:3793-3802.

McIntyre, K. (2015). An Oncology Nurses' Guide to New Targeted Agents for Metastatic Colorectal Cancer. Clinical journal of oncology nursing 19,5:571-579.

NICE. TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer. October 2015

GI Cancers, November 2015 3 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Pereira AA, Rego JF, Munhoz RR, et al. (2015). The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. Acta Oncologica 54,10:1737-1746.

Petrioli R, Francini E, Roviello F, et al. (2015). Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged >75years with impaired performance status. Journal of Geriatric Oncology 6,5:380-386.

Pietrantonio F, Cremolini C, Petrelli F, et al. (2015). First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology-Hematology 96,1:156-166.

Ryu MH, Baba E, Lee KH, et al. (2015). Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Annals of Oncology 26,10:2097-2101.

Sadahiro S, Tsuchiya T, Sasaki K, et al. (2015). Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502. Annals of Oncology 26,11:2274-2280.

Schmoll HJ, Tabernero J, Maroun J, et al. (2015). Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Journal of Clinical Oncology 33,32:3733-3740.

Tournigand C, Chibaudel B, Samson B, et al. (2015). Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncology 16,15:1493-1505.

Yokota T, Ando N, Igaki H, et al. (2015). Prognostic Factors in Patients Receiving Neoadjuvant 5- Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907). Oncology 89,3:143-151.

Pathology, Staging, Polymorphisms & Biomarkers

Astin MP, Martins T, Welton N, et al. (2015). Diagnostic value of symptoms of oesophagogastric cancers in primary care: a systematic review and meta-analysis. British Journal of General Practice 65,639:e677-91.

Carrasco J, Gizzi M, Pairet G, et al. (2015). Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. British journal of cancer 113,9:1298-1304.

Colvin H, Yamamoto K, Wada N, et al. (2015). Hereditary Gastric Cancer Syndromes. Surgical oncology clinics of North America 24,4:765-777.

Couch DG, Murphy JH, Boyle KM, et al. (2015). Straight to flexible sigmoidoscopy: rationalization of 2-week wait referrals in suspected colorectal cancer. Colorectal Disease 17,11:980-983.

Erstad DJ, Tumusiime G and Cusack JC Jr. (2015). Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon. Annals of Surgical Oncology 22,11:3433- 3450.

Hawk NN, Long TE, Imam MH, et al. (2015). Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. American Journal of Clinical Oncology 38,6:543-549.

Hecht JR, Douillard JY, Schwartzberg L, et al. (2015). Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer treatment reviews 41,8:653-659.

GI Cancers, November 2015 4 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Heinemann V, Stintzing S, Modest DP, et al. (2015). Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). European journal of cancer 51,14:1927-1936.

Jasperson K and Burt RW. (2015). The Genetics of Colorectal Cancer. Surgical oncology clinics of North America 24,4:683-703.

Lim SH, Chua W, Henderson C, et al. (2015). Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Critical Reviews in Oncology-Hematology 96,1:67-80.

Molinari C, Matteucci F, Caroli P, et al. (2015). Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Clinical Colorectal Cancer 14,4:227-238.

Veitch AM, Uedo N, Yao K, et al. (2015). Optimizing early upper gastrointestinal cancer detection at endoscopy. Nature Reviews Gastroenterology & Hepatology 12,11:660-667.

Prognosis, Survival & Risk Factors

Ang CW, Seretis C, Wanigasooriya K, et al. (2015). The most frequent cause of 90-day unplanned hospital readmission following colorectal cancer resection is chemotherapy complications. Colorectal Disease 17,9:779-786.

Baron JA, Barry EL, Mott LA, et al. (2015). A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. New England Journal of Medicine 373,16:1519-1530.

Downing A, Morris EJ, Aravani A, et al. (2015). The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus. Clinical Oncology (Royal College of Radiologists) 27,12:708-712.

El-Shami K, Oeffinger KC, Erb NL, et al. (2015). American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA: a Cancer Journal for Clinicians 65,6:427-455.

Ford AC, Forman D, Hunt R, et al. (2015). Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 7,005583.

Jawed I, Wilkerson J, Prasad V, et al. (2015). Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncology 1,6:787-795.

Kawai K, Sunami E, Yamaguchi H, et al. (2015). Nomograms for colorectal cancer: A systematic review. World Journal of Gastroenterology 21,41:11877-11886.

Li P, Wu H, Zhang H, et al. (2015). Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 64,9:1419-1425.

Pabla B, Bissonnette M and Konda VJ. (2015). Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World Journal of Clinical Oncology 6,5:133-141.

Stier EA, Sebring MC, Mendez AE, et al. (2015). Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review. American Journal of Obstetrics & Gynecology 213,3:278-309.

Radiotherapy & Imaging

dePrisco, G. (2015). MRI Local Staging and Restaging in Rectal Cancer. Clinics in Colon & Rectal Surgery 28,3:194-200.

GI Cancers, November 2015 5 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Froseth TC, Strickert T, Solli KS, et al. (2015). A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients. Radiation Oncology 10,1:217.

Moreno CC, Sullivan PS, Kalb BT, et al. (2015). Magnetic resonance imaging of rectal cancer: staging and restaging evaluation. Abdominal Imaging 40,7:2613-2629.

NICE. IPG532: Low energy contact X ray brachytherapy (the Papillon technique) for early stage rectal cancer. September 2015

Yu E, DiPetrillo TA, Ramey S, et al. (2015). Comparison of endorectal ultrasound versus pelvic magnetic resonance imaging for radiation treatment planning in locally advanced rectal cancer. Practical Radiation Oncology 5,5:e451-5.

Yu JI, Lim do H, Ahn YC, et al. (2015). Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. Radiotherapy & Oncology 117,1:171-177.

Supportive Care & Symptom Management

Borstlap WA, Stellingwerf ME, Moolla Z, et al. (2015). Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: a systematic review. Colorectal Disease 17,12:1044- 1054.

Bowen JM, White I, Smith L, et al. (2015). Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. Supportive Care in Cancer 23,11:3165-3172.

Gordon LG, Patrao T, Kularatna S, et al. (2015). A telephone-delivered multiple health behaviour change intervention for colorectal cancer survivors: making the case for cost-effective healthcare. European Journal of Cancer Care 24,6:854-861.

Hofheinz RD, Gencer D, Schulz H, et al. (2015). Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. Journal of Clinical Oncology 33,22:2444-2449.

Levolger S, van Vugt JL, de Bruin RW, et al. (2015). Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. British Journal of Surgery 102,12:1448-1458.

Lin KY, Granger CL, Denehy L, et al. (2015). Pelvic floor muscle training for bowel dysfunction following colorectal cancer surgery: A systematic review. Neurourology & Urodynamics 34,8:703-712.

McLellan B, Ciardiello F, Lacouture ME, et al. (2015). Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Annals of Oncology 26,10:2017-2026.

McNair AG, Whistance RN, Forsythe RO, et al. (2015). Synthesis and summary of patient-reported outcome measures to inform the development of a core outcome set in colorectal cancer surgery. Colorectal Disease 17,11:O217-29.

Miroddi M, Sterrantino C, Simonelli I, et al. (2015). Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Critical Reviews in Oncology-Hematology 96,2:355-371.

O'Carroll RE, Chambers JA, Brownlee L, et al. (2015). Anticipated regret to increase uptake of colorectal cancer screening (ARTICS): A randomised controlled trial. Social science & medicine 142,118-127.

GI Cancers, November 2015 6 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Russell L, Gough K, Drosdowsky A, et al. (2015). Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment. Journal of Cancer Survivorship 9,3:462-470.

Santin O, Murray L, Prue G, et al. (2015). Self-reported psychosocial needs and health-related quality of life of colorectal cancer survivors. European Journal of Oncology Nursing 19,4:336-342.

Sclafani F, Peckitt C, Cunningham D, et al. (2015). Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International journal of radiation oncology, biology, physics 93,2:303-312.

Shan B, Shan L, Morris D, et al. (2015). Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma. Journal of Gastrointestinal Oncology 6,5:544-560.

Skinner CS, Halm EA, Bishop WP, et al. (2015). Impact of Risk Assessment and Tailored versus Nontailored Risk Information on Colorectal Cancer Testing in Primary Care: A Randomized Controlled Trial. Cancer Epidemiology, Biomarkers & Prevention 24,10:1523-1530.

Sodergren SC, Vassiliou V, Dennis K, et al. (2015). Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Supportive Care in Cancer 23,12:3613-3623.

Sun V, Grant M, Wendel CS, et al. (2015). Dietary and Behavioral Adjustments to Manage Bowel Dysfunction After Surgery in Long-Term Colorectal Cancer Survivors. Annals of Surgical Oncology 22,13:4317-4324.

Tsimopoulou I, Pasquali S, Howard R, et al. (2015). Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Annals of Surgical Oncology 22,13:4117-4123.

Yamana I, Takeno S, Hashimoto T, et al. (2015). Randomized Controlled Study to Evaluate the Efficacy of a Preoperative Respiratory Rehabilitation Program to Prevent Postoperative Pulmonary Complications after Esophagectomy. Digestive surgery 32,5:331-337.

Young CJ, De-Loyde KJ, Young JM, et al. (2015). Improving Quality of Life for People with Incurable Large-Bowel Obstruction: Randomized Control Trial of Colonic Stent Insertion. Diseases of the Colon & Rectum 58,9:838-849.

Surgery

Figueiredo PC, Pimentel-Nunes P, Libanio D, et al. (2015). A systematic review and meta-analysis on outcomes after Rx or R1 endoscopic resection of superficial gastric cancer. European journal of gastroenterology & hepatology 27,11:1249-1258.

Fleshman J, Branda M, Sargent DJ, et al. (2015). Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA 314,13:1346-1355.

Geng HZ, Nasier D, Liu B, et al. (2015). Meta-analysis of elective surgical complications related to defunctioning loop ileostomy compared with loop colostomy after low anterior resection for rectal carcinoma. Annals of the Royal College of Surgeons of England 97,7:494-501.

Gockel I, Ahlbrand CJ, Arras M, et al. (2015). Quality Management and Key Performance Indicators in Oncologic Esophageal Surgery. Digestive Diseases & Sciences 60,12:3536-3544.

Kim ER, Lee H, Min BH, et al. (2015). Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. British Journal of Surgery 102,11:1394-1401.

Kulvatunyou N, Pandit V, Moutamn S, et al. (2015). A multi-institution prospective observational study of small bowel obstruction: Clinical and computerized tomography predictors of which patients may require early surgery. The Journal of Trauma and Acute Care Surgery 79,3:393-398.

GI Cancers, November 2015 7 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Liu CJ, Chou YJ, Teng CJ, et al. (2015). Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: A nationwide population- based study. Cancer 121,16:2782-2790.

Markar S, Gronnier C, Duhamel A, et al. (2015). The Impact of Severe Anastomotic Leak on Long-term Survival and Cancer Recurrence After Surgical Resection for Esophageal Malignancy. Annals of Surgery 262,6:972-980.

Messager M, Pasquer A, Duhamel A, et al. (2015). Laparoscopic Gastric Mobilization Reduces Postoperative Mortality After Esophageal Cancer Surgery: A French Nationwide Study. Annals of Surgery 262,5:817-823.

Mocellin S, McCulloch P, Kazi H, et al. (2015). Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 8,001964.

Moug SJ, McCarthy K, Coode-Bate J, et al. (2015). Laparoscopic versus open surgery for colorectal cancer in the older person: A systematic review. Annals of Medicine & Surgery 4,3:311-318.

Paulson EC, Veenstra CM, Vachani A, et al. (2015). Trends in surveillance for resected colorectal cancer, 2001-2009. Cancer 121,19:3525-3533.

Pittet O, Nocito A, Balke H, et al. (2015). Rectal enema is an alternative to full mechanical bowel preparation for primary rectal cancer surgery. Colorectal Disease 17,11:1007-1010.

Qu H, Liu Y and Bi DS. (2015). Clinical risk factors for anastomotic leakage after laparoscopic anterior resection for rectal cancer: a systematic review and meta-analysis. Surgical endoscopy 29,12:3608-3617.

Rickles AS, Dietz DW, Chang GJ, et al. (2015). High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action. Annals of Surgery 262,6:891-898.

Russo S, Blackstock AW, Herman JM, et al. (2015). ACR Appropriateness Criteria Local Excision in Early Stage Rectal Cancer. American Journal of Clinical Oncology 38,5:520-525.

Siddika A, Tolia-Shah D, Pearson TE, et al. (2015). Remote surveillance after colorectal cancer surgery: an effective alternative to standard clinic-based follow-up. Colorectal Disease 17,10:870- 875.

Stevenson AR, Solomon MJ, Lumley JW, et al. (2015). Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. JAMA 314,13:1356-1363.

Thrumurthy SG, Chaudry MA, Chau I, et al. (2015). Does surgery have a role in managing incurable gastric cancer? Nature Reviews Clinical Oncology 12,11:676-682.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin.

Sources used for this bulletin:

OVID MEDLINE, NICE, SIGN, Healthcare Improvement Scotland

GI Cancers, November 2015 8 Kirsty Coltart, Subject Librarian, NHSGGC Library Network